Oppenheimer & Co
ADMA icon

Oppenheimer & Co’s ADMA Biologics ADMA Stock Holding History

Oppenheimer & Co’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$546K Sell
54,480
-2,318
-4% -$21.4K 0.01% 1174
2026
Q2 		$475K Sell
56,798
-4,272
-7% -$38.9K 0.01% 1276
2026
Q1 		$550K Buy
+61,070
New +$964K 0.01% 1152
2025
Q4 		– Sell
-49,230
Closed -$722K – 1534
2025
Q3 		$722K Buy
49,230
+835
+2% +$14.3K 0.01% 1041
2025
Q2 		$881K Sell
48,395
-6,892
-12% -$141K 0.01% 914
2025
Q1 		$1.1M Buy
55,287
+16,871
+44% +$292K 0.02% 766
2024
Q4 		$659K Sell
38,416
-56,522
-60% -$1.06M 0.01% 968
2024
Q3 		$1.9M Buy
94,938
+43,836
+86% +$682K 0.03% 571
2024
Q2 		$571K Sell
51,102
-43,108
-46% -$362K 0.01% 965
2024
Q1 		$622K Sell
94,210
-27,726
-23% -$152K 0.01% 918
2023
Q4 		$551K Buy
121,936
+4,801
+4% +$17.8K 0.01% 940
2023
Q3 		$419K Sell
117,135
-2,255
-2% -$8.68K 0.01% 1009
2023
Q2 		$441K Sell
119,390
-6,500
-5% -$24.1K 0.01% 1024
2023
Q1 		$417K Buy
125,890
+3,065
+2% +$10.6K 0.01% 1009
2022
Q4 		$477K Sell
122,825
-77,500
-39% -$239K 0.01% 923
2022
Q3 		$487K Buy
200,325
+30,903
+18% +$74.1K 0.01% 907
2022
Q2 		$335K Buy
+169,422
New +$333K 0.01% 1064
2020
Q2 		– Sell
-10,836
Closed -$31K – 1254
2020
Q1 		$31K Buy
10,836
+810
+8% +$2.8K ﹤0.01% 1167
2019
Q4 		$40K Buy
+10,026
New +$43.7K ﹤0.01% 1258

Other funds holding ADMA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Ranger Investment Management
Ranger Investment Management Dallas, Texas $1.07B AUM 31.98% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Marathon Capital Management
Marathon Capital Management Hunt Valley, Maryland $488M AUM 28.5% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Bridge City Capital
Bridge City Capital Lake Oswego, Oregon $480M AUM 47.16% 1-Year Est. Return

Oppenheimer & Co's ADMA Position: Q3 2026 in Review

Oppenheimer & Co reduced its ADMA Biologics (ADMA) stake by 4.1% in Q3 2026, selling an estimated $21.4K and leaving 54,480 shares worth $546K. The position accounts for 0.01% of the portfolio, ranked #1174.

Oppenheimer & Co first reported a position in ADMA in Q4 2019 and has held it in 19 quarters since. The position peaked at $1.9M in Q3 2024. 144 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.

  • Oppenheimer & Co held 54,480 shares of ADMA Biologics worth $546K as of Q3 2026.
  • Oppenheimer & Co sold 2,318 ADMA Biologics shares in Q3 2026, an estimated $21.4K.
  • ADMA Biologics made up 0.01% of Oppenheimer & Co's portfolio in Q3 2026, its #1174 holding.
  • Oppenheimer & Co first reported a position in ADMA Biologics in Q4 2019 and has held it in 19 quarters since.
  • Oppenheimer & Co's ADMA Biologics position peaked at $1.9M in Q3 2024.
  • 144 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.

Based on Oppenheimer & Co's 13F filing for Q3 2026, filed 26 Oct 2026.